Posted by Michael Wonder on 27 Mar 2026
Awiqli approved in the US, the first and only once weekly basal insulin treatment for adults with type 2 diabetes
27 March 2026 - Novo Nordisk expects to launch Awiqli nationwide in the US in the second half of 2026.
Novo Nordisk today announced that the US FDA has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only once weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control in adults living with type 2 diabetes.
